Searched for
DIAGNOSTIC TESTS IN INDIA
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIt is probably time to be bullish as an investor. But remember two things. One: Valuations are still not cheap. Two: Because it is over and...
- Avience Biomedicals shares make blockbuster debut, list at 90% premium on NSE SMEAvience Biomedicals made a spectacular debut on the NSE SME platform, with its shares rocketing 90% on listing day. The Rs 30.24 crore IPO,...
- For investors who focus on the long term: 5 mid-cap stocks from different sectors with upside potential up to 28%When prices fall, caution comes naturally. Investors hesitate, portfolios are reviewed less often, and even optimists become careful. But w...
- India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil SubramaniamIndia's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Avience Biomedicals IPO: Check GMP, price band and other detailsThe grey market premium (GMP) for the issue stood at 36% ahead of the opening, implying an unofficial market price of around Rs 283 against...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- PMS vs mutual funds: 5 reasons to invest, and 5 red flags to watchPortfolio Management Services (PMS) offer structural advantages over mutual funds, allowing for concentrated portfolios, significant cash h...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- European traveller shares India medical testing experience: Mumbai clinic visit, blood tests and test resultsA European traveler's positive experience with India's efficient medical testing system has gone viral. Liza shared how she received a rapi...
- Infosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform globalPrecision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...
- 5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
- Should you buy OPD cover in health insurance? Over 40% of healthcare costs are paid out-of-pocket in IndiaOPD cover in health insurance addresses out-of-pocket expenses for doctor visits, diagnostics, and medicines without hospitalization. While...
- Q-Line Biotec shares to list today. Check GMP ahead of debutQ-Line Biotech is poised for a strong stock market debut on Friday. Investor demand appears robust, with grey market trends showing a signi...
- Ebola at the gates: Why India must not let its guard downIndia is enhancing its surveillance protocols following an Ebola outbreak in the Democratic Republic of Congo and Uganda. One of two suspec...
Load More
